Congenital erythropoietin over-expression causes “anti-pulmonary hypertensive” structural and functional changes in mice, both in normoxia and hypoxia

Norbert Weissmann; Daniel Manz; Daniela Buchspies; Stephan Keller; Tanja Mehling; Robert Voswinckel; Karin Quanz; Hossein A. Ghofrani; Ralph T. Schermuly; Ludger Fink; Werner Seeger; Max Gassmann

doi:10.1160/TH05-02-0104

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(03): 630-638
DOI: 10.1160/TH05-02-0104

Cell Signalling and Vessel Remodelling

Schattauer GmbH

Congenital erythropoietin over-expression causes “anti-pulmonary hypertensive” structural and functional changes in mice, both in normoxia and hypoxia

Norbert Weissmann

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Daniel Manz^*

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Daniela Buchspies

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Stephan Keller

²Institute of Veterinary Physiology, Vetsuisse Faculty and Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland

,

Tanja Mehling

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Robert Voswinckel

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Karin Quanz

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Hossein A. Ghofrani

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Ralph T. Schermuly

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Ludger Fink

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Werner Seeger

¹University of Giessen Lung Center, Department of Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany

,

Max Gassmann

²Institute of Veterinary Physiology, Vetsuisse Faculty and Center of Integrative Human Physiology, University of Zurich, Zurich, Switzerland

› Author Affiliations

Abstract

Summary

Acute alveolar hypoxia causes pulmonary vasoconstriction that matches lung perfusion to ventilation to optimize gas exchange. Chronic alveolar hypoxia induces pulmonary hypertension, characterized by increased muscularization of the pulmonary vasculature and right ventricular hypertrophy. Elevated erythropoietin (EPO) plasma levels increase hematocrit and blood viscosity and may affect structure and function of the pulmonary circulation. To differentiate between the direct effects of hypoxia and those linked to a hypoxia-induced increase in EPO/hematocrit levels, we investigated the lung vasculature in transgenic mice constitutively over-expressing EPO (termed tg6) upon exposure to normoxia and chronic hypoxia. Despite increased hematocrit levels (∼0.86),tg6 mice kept in normoxia did not develop selective right ventricular hypertrophy. The portion of vessels with a diameter of 51–95 μm and >155 μm was increased whereas the portion of small vessels (30–50 μm) was decreased. Pulmonary vascular resistance and the strength of hypoxic vasoconstriction measured in isolated perfused lungs were decreased. Vasoconstrictions induced by the thromboxane mimetic U46619 tended to be reduced. After chronic hypoxia (FiO₂ = 0.10, 21days), vascular resistance and vasoconstrictor responses to acute hypoxia and U46619 were reduced in tg6 mice compared to wildtype controls. Chronic hypoxia increased the degree of pulmonary vascular muscularization in wildtype but not in tg6 mice that already exhibited less muscularization in normoxia. In conclusion, congenital over-expression of EPO exerts an “anti-pulmonary hypertensive” effect, both structurally and functionally, particularly obvious upon chronic hypoxia.

Keywords

Hypoxia - mouse - excessive erythrocytosis - vasoconstriction

Full Text

References

References
1 Agusti AG, Roca J, Bosch J. et al. The lung in patients with cirrhosis.. J Hepatol 1990; 10: 251-7.
2 Hampl V, Herget J. Acute pneumonia reversibly inhibits hypoxic vasoconstriction in isolated rat lungs.. Physiol Res 1992; 41: 147-50.
3 Durmowicz AG, Stenmark KR. Mechanisms of structural remodeling in chronic pulmonary hypertension.. Pediatr Rev 1999; 20: e91-e102.
4 Weissmann N, Grimminger F, Olschewski A. et al. Hypoxic pulmonary vasoconstriction: a multifactorial response?. Am J Physiol Lung Cell Mol Physiol 2001; 281: L314-L317.
5 Jefferson JA, Escudero E, Hurtado ME. et al. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels.. Lancet 2002; 359: 407-8.
6 Santolaya RB, Lahiri S, Alfaro RT. et al. Respiratory adaptation in the highest inhabitants and highest Sherpa mountaineers.. Respir Physiol 1989; 77: 253-62.
7 Aldashev AA, Sarybaev AS, Sydykov AS. et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype.. Am J Respir Crit Care Med 2002; 166: 1396-402.
8 Tsantes AE, Papadhimitriou SI, Tassiopoulos ST. et al. Red cell macrocytosis in hypoxemic patients with chronic obstructive pulmonary disease.. Respir Med 2004; 98: 1117-23.
9 Winnicki M, Shamsuzzaman A, Lanfranchi P. et al. Erythropoietin and obstructive sleep apnea.. Am J Hypertens 2004; 17: 783-6.
10 Fedullo PF, Auger WR, Channick RN. et al. Chronic thromboembolic pulmonary hypertension.. Clin Chest Med 2001; 22: 561-81.
11 Humbert M, Morrell NW, Archer SL. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension.. J Am Coll Cardiol 2004; 43: 13S-24S.
12 Moraes D, Loscalzo J. Pulmonary hypertension: newer concepts in diagnosis and management.. Clin Cardiol 1997; 20: 676-82.
13 Wagner KF, Katschinski DM, Hasegawa J. et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin.. Blood 2001; 97: 536-42.
14 Ruschitzka FT, Wenger RH, Stallmach T. et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.. Proc Natl Acad Sci U S A 2000; 97: 11609-13.
15 Vogel J, Kiessling I, Heinicke K. et al. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity.. Blood 2003; 102: 2278-84.
16 Wiessner C, Allegrini PR, Ekatodramis D. et al. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin.. J Cereb Blood Flow Metab 2001; 21: 857-64.
17 Shibata J, Hasegawa J, Siemens HJ. et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis.. Blood 2003; 101: 4416-22.
18 Quaschning T, Ruschitzka F, Stallmach T. et al. Erythropoietin- induced excessive erythrocytosis activates the tissue endothelin system in mice.. FASEB J 2003; 17: 259-61.
19 Grimm C, Wenzel A, Stanescu D. et al. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration.. J Neurosci 2004; 24: 5651-8.
20 Naeye RL. Polycythemia and hypoxia. Individual effects on heart and pulmonary arteries.. Am J Pathol 1967; 50: 1027-33.
21 Petit RD, Warburton RR, Ou LC. et al. Exogenous erythropoietin fails to augment hypoxic pulmonary hypertension in rats.. Respir Physiol 1993; 91: 271-82.
22 Petit RD, Warburton RR, Ou LC. et al. Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia.. J Appl Physiol 1995; 79: 229-35.
23 Grimminger F, Spriestersbach R, Weissmann N. et al. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs.. J Appl Physiol 1995; 78: 1509-15.
24 Quinlan TR, Li D, Laubach VE. et al. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia.. Am J Physiol Lung Cell Mol Physiol 2000; 279: L641-L650.
25 Ozaki M, Kawashima S, Yamashita T. et al.. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium.. Hypertension 2001; 37: 322-7.
26 Hasegawa J, Wagner KF, Karp D. et al. Altered pulmonary vascular reactivity in mice with excessive erythrocytosis.. Am J Respir Crit Care Med 2004; 169: 829-35.
27 Weissmann N, Akkayagil E, Quanz K. et al. Basic features of hypoxic pulmonary vasoconstriction in mice.. Respir Physiol Neurobiol 2004; 139: 191-202.
28 Fink L, Kohlhoff S, Stein MM. et al. cDNA array hybridization after laser-assisted microdissection from nonneoplastic tissue.. Am J Pathol 2002; 160: 81-90.
29 Swigart RH. Polycythemia and right ventricular hypertrophy.. Circ Res 1965; 17: 30-8.
30 Palevsky HI, Fishman AP. Chronic cor pulmonale. Etiology and management.. JAMA 1990; 263: 2347-53.
31 Gassmann M, Heinicke KA, Soliz J. et al.. Non-erythroid functions of erythropoietin.. Hypoxia: Through the Lifecycle 2003; 543: 323-30.
32 Grimm C, Wenzel A, Groszer M. et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.. Nat Med 2002; 8: 718-24.
33 Herve P, Humbert M, Sitbon O. et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis.. Clin Chest Med 2001; 22: 451-8.
34 Pidgeon GP, Tamosiuniene R, Chen G. et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.. Circulation 2004; 110: 2701-7.
35 Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension.. Pharmacol Ther 2001; 92: 1-20.
36 Calvillo L, Latini R, Kajstura J. et al.. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.. Proc Natl Acad Sci U S A 2003; 100: 4802-6.
37 Leist M, Ghezzi P, Grasso G. et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic.. Science 2004; 305: 239-42.
38 Saldivar E, Cabrales P, Tsai AG. et al.. Microcirculatory changes during chronic adaptation to hypoxia.. Am J Physiol Heart Circ Physiol 2003; 285: H2064-H2071.